Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bluebird bio, Inc.    BLUE

BLUEBIRD BIO, INC.

(BLUE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/11/2020 02/12/2020 02/13/2020 02/14/2020 02/18/2020 Date
90.06(c) 91.57(c) 89.5(c) 89.31(c) 88.22(c) Last
383 229 481 721 469 504 418 066 530 188 Volume
-0.66% +1.68% -2.26% -0.21% -1.22% Change
More quotes
Financials (USD)
Sales 2020 47,6 M
EBIT 2020 -954 M
Net income 2020 -937 M
Finance 2020 506 M
Yield 2020 -
Sales 2021 225 M
EBIT 2021 -772 M
Net income 2021 -753 M
Finance 2021 437 M
Yield 2021 -
P/E ratio 2020 -5,66x
P/E ratio 2021 -7,14x
EV / Sales2020 92,0x
EV / Sales2021 19,7x
Capitalization 4 881 M
More Financials
Company
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these... 
Sector
Biotechnology & Medical Research
Calendar
02/26 | 02:30pmPresentation
More about the company
Surperformance© ratings of bluebird bio, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on BLUEBIRD BIO, INC.
02/18BLUEBIRD BIO : Securities offered to employees pursuant to employee benefit plan..
PU
02/18BLUEBIRD : 4Q Earnings Snapshot
AQ
02/18BLUEBIRD BIO : Management's Discussion and Analysis of Financial Condition and R..
AQ
02/18BLUEBIRD BIO, INC. : Results of Operations and Financial Condition, Financial St..
AQ
02/18BLUEBIRD BIO : Reports Fourth Quarter and Full Year 2019 Financial Results and H..
BU
02/05BLUEBIRD BIO : Announces Upcoming Investor Events
BU
01/21BLUEBIRD BIO, INC. : Entry into a Material Definitive Agreement, Financial State..
AQ
01/13BLUEBIRD BIO, INC. : Results of Operations and Financial Condition, Regulation F..
AQ
01/13BLUEBIRD BIO : Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ ..
BU
2019BLUEBIRD BIO : Announces Investor Events in January
BU
2019GLAXOSMITHKLINE : Study Shows Blood Cancer Drug Works in Heavily Treated Patient..
DJ
2019BLUEBIRD BIO : and Bristol-Myers Squibb Present Updated Data from Ongoing Phase ..
AQ
2019BLUEBIRD BIO, INC. : Regulation FD Disclosure, Other Events, Financial Statement..
AQ
2019BLUEBIRD BIO : and Bristol-Myers Squibb Present Updated Data from Ongoing Phase ..
BU
2019BLUEBIRD BIO : Presents New Data Demonstrating Long-Term Transfusion Independenc..
BU
More news
News in other languages on BLUEBIRD BIO, INC.
2018ORIGINAL-RESEARCH : Medigene AG (von EQUITS GmbH): Kaufen
2018ORIGINAL-RESEARCH : Medigene AG (von EQUITS GmbH): Kaufen
2018BLUEBIRD BIO : gibt im New England Journal of Medicine veröffentlichte Zwischend..
2017Wall Street finit en hausse avec les techs et l'énergie
2017Les valeurs à suivre à Wall Street
More news
Sector news : Bio Therapeutic Drugs
02/18Sanofi to Work on Coronavirus Vaccine
DJ
02/18Gilead's Coronavirus Drug Trial Slowed Due to Lack of Eligible Recruits
DJ
02/12Coronavirus-Drug Development Becomes a Top Focus at Gilead
DJ
02/12GILEAD SCIENCES : Correction to Report About Gilead Sciences' Work on a Coronavi..
DJ
02/12Gilead Sciences Scrambles to Supply Experimental Coronavirus Drug
DJ
More sector news : Bio Therapeutic Drugs
Chart BLUEBIRD BIO, INC.
Duration : Period :
bluebird bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BLUEBIRD BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 136,95  $
Last Close Price 88,22  $
Spread / Highest target 161%
Spread / Average Target 55,2%
Spread / Lowest Target -3,65%
EPS Revisions
Managers
NameTitle
Nick Leschly President, Chief Executive Officer & Director
Daniel S. Lynch Chairman
Jason F. Cole Chief Operating & Legal Officer
William Denise Baird Chief Financial Officer
David M. Davidson Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BLUEBIRD BIO, INC.0.54%4 881
GILEAD SCIENCES3.97%84 777
VERTEX PHARMACEUTICALS12.32%63 762
REGENERON PHARMACEUTICALS6.41%43 287
WUXI APPTEC CO., LTD.23.75%26 550
GENMAB10.23%15 693